X4 Pharmaceuticals (XFOR) Tops Q1 EPS by 16c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q1 EPS of $0.04, $0.16 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $28.81 million versus the consensus estimate of $12.03 million.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Bernstein SocGen on Performance Food Group (PFGC): 'Not the quarter we were hoping for, but LT story intact'
• MongoDB (MDB) PT Raised at RBC Capital; 'Shares represent an attractive buying opportunity'